Annovis Bio, Inc.(ANVS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

ANVS Annovis Bio, Inc.

Market Closed 02-14 16:00:00 EST

2.73

+0.13

+5.00%

盘后2.74

+0.01+0.36%

19:58 EST

High2.79	Low2.61	Vol506.47K
Open2.65	D1 Closing2.60	Amplitude6.92%
Mkt Cap52.00M	Tradable Cap45.51M	Total Shares19.05M
T/O1.37M	T/O Rate3.04%	Tradable Shares16.67M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"ANVS","market":"US","secType":"STK","nameCN":"Annovis Bio, Inc.","latestPrice":2.73,"timestamp":1739566800000,"preClose":2.6,"halted":0,"volume":506469,"hourTrading":{"tag":"盘后","latestPrice":2.7399,"preClose":2.73,"latestTime":"19:58 EST","volume":2803,"amount":7668.7434,"timestamp":1739581092045},"delay":0,"floatShares":16671300,"shares":19047242,"eps":-3.972968,"marketStatus":"Market Closed","change":0.13,"latestTime":"02-14 16:00:00 EST","open":2.65,"high":2.79,"low":2.61,"amount":1368958.1044394998,"amplitude":0.069231,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.972968,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1739869200000},"marketStatusCode":7,"adr":0,"listingDate":1580274000000,"exchange":"NYSE","adjPreClose":2.6,"preHourTrading":{"tag":"盘前","latestPrice":2.669,"preClose":2.6,"latestTime":"09:29 EST","volume":19452,"amount":52597.604988,"timestamp":1739543353033},"postHourTrading":{"tag":"盘后","latestPrice":2.7399,"preClose":2.73,"latestTime":"19:58 EST","volume":2803,"amount":7668.7434,"timestamp":1739581092045},"volumeRatio":0.8289463865672727,"impliedVol":2.8096,"impliedVolPercentile":0.7729},"requestUrl":"/m/hq/s/ANVS","defaultTab":"news","newsList":[{"id":"2510065856","title":"Annovis Bio Cut to Hold From Buy by D. Boral Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2510065856","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510065856?lang=en_us&edition=fundamental","pubTime":"2025-02-10 20:17","pubTimestamp":1739189820,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ANVS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 10, 2025 07:17 ET (12:17 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANVS","BK4139"],"gpt_icon":0},{"id":"2509803743","title":"Annovis to Present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2509803743","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509803743?lang=en_us&edition=fundamental","pubTime":"2025-02-07 21:00","pubTimestamp":1738933200,"startTime":"0","endTime":"0","summary":"MALVERN, Pa., Feb. 07, 2025  -- via IBN – Annovis Bio Inc.  , a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease  and Parkinson's disease , today announced that its CEO, Maria Maccecchini, Ph.D., will present at the Oppenheimer's 35th Annual Healthcare Life Sciences Conference.Attendees can access the live presentation through the conference's virtual platform.Dr. Maccecchini will discuss the Company’s latest advancements, highlighting the progress of the pivotal Phase 3 trial in early AD and strategic initiatives toward a New Drug Application  for buntanetap as both a symptomatic and potentially disease-modifying treatment.Oppenheimer's Annual Healthcare Life Sciences Conference is a premier event that brings together leading companies and investors in the healthcare and life sciences sectors. The conference features presentations from industry executives, providing insights into current trends, in","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/annovis-present-oppenheimers-35th-annual-130000285.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0066902890.USD","IE00B0JY6M65.USD","LU0264410563.USD","LU0823038988.USD","SG9999004220.SGD","LU1102505929.USD","BK4127","LU0531971678.HKD","PD","LU1169589451.USD","LU1169590202.USD","BK4585","LU1481012133.USD","BK4207","BK4137","LU0261950470.USD","ANVS","BK4139","OPY","LU0143863198.USD","IE00B7N09G41.SGD","LU0823039010.USD","LU0828237940.HKD","LU0251143458.SGD","LU0143863784.USD","BK4023","HCSG","LU1102505762.USD","LU1868838027.USD","LU1868837722.USD","BK4548","BK4535","BK4588","LU0181495838.USD","LU0164881194.USD","IE00BYTNYM70.SGD","BK4523","IBN","LU1868837565.USD","LU0048575426.USD"],"gpt_icon":0},{"id":"2509595275","title":"Annovis Bio announces first patients entered Phase 3 study of buntanetap","url":"https://stock-news.laohu8.com/highlight/detail?id=2509595275","media":"TipRanks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509595275?lang=en_us&edition=fundamental","pubTime":"2025-02-06 21:20","pubTimestamp":1738848041,"startTime":"0","endTime":"0","summary":"Annovis Bio  announced that the first two patients have been entered into the Phase 3 study evaluating buntanetap in early AD. “The launch of our highly anticipated AD study is a significant milestone in advancing buntanetap toward market approval and addressing the unmet medical need of millions of patients. Our previous trials have delivered compelling results, and we have meticulously designed a comprehensive protocol to evaluate both the symptomatic and potential disease-modifying effects of our drug candidate,” said Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis.Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with  Your Smart Portfolio. Annovis Bio announces pricing of $21M offering of stock, warrants. Annovis Bio announces FDA acceptance of protocol for Phase 3 AD study. Annovis Bi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/annovis-bio-announces-first-patients-132041350.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/annovis-bio-announces-first-patients-132041350.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ANVS","BK4139"],"gpt_icon":0},{"id":"2509236983","title":"Annovis Bio Enrolls First Patients in Phase 3 Trial of Buntanetap for Early Alzheimer's Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2509236983","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509236983?lang=en_us&edition=fundamental","pubTime":"2025-02-06 00:06","pubTimestamp":1738771584,"startTime":"0","endTime":"0","summary":"Annovis Bio  said Wednesday it enrolled the first two participants in its phase 3 trial of buntanetap for early Alzheimer's disease.The trial will evaluate the safety and efficacy of a daily dose of buntanetap, with treatment lasting for 18 months.The study includes a 6-month assessment of symptomatic effects followed by a 12-month evaluation of potential disease-modifying effects. Annovis said it plans to enroll more than 750 patients across about 100 sites in the US.The US Food and Drug Administration approved the Phase 3 protocol for the trial in January, the company added.Shares of Annovis were down 1.4% in recent trading.Price: 3.10, Change: -0.04, Percent Change: -1.43","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","ANVS"],"gpt_icon":0},{"id":"2509886286","title":"Annovis Bio Launches Phase 3 Alzheimer’s Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2509886286","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509886286?lang=en_us&edition=fundamental","pubTime":"2025-02-05 21:28","pubTimestamp":1738762117,"startTime":"0","endTime":"0","summary":"Annovis Bio ( ($ANVS) ) just unveiled an announcement. On February 5, 2025, Annovis Bio Inc. announced the commencement of its pivotal Phase 3 stud...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/annovis-bio-launches-phase-3-alzheimers-study?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/annovis-bio-launches-phase-3-alzheimers-study?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ANVS"],"gpt_icon":0},{"id":"2509833742","title":"Annovis Announces First Patients Entered Into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2509833742","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509833742?lang=en_us&edition=fundamental","pubTime":"2025-02-05 21:00","pubTimestamp":1738760405,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250205:nTUA2SRKML:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ANVS"],"gpt_icon":0},{"id":"2509285314","title":"Annovis Announces First Patients Entered into Pivotal Phase 3 Study of Buntanetap for Early Alzheimer’s Disease","url":"https://stock-news.laohu8.com/highlight/detail?id=2509285314","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509285314?lang=en_us&edition=fundamental","pubTime":"2025-02-05 21:00","pubTimestamp":1738760400,"startTime":"0","endTime":"0","summary":"MALVERN, Pa., Feb.  05, 2025  (GLOBE NEWSWIRE) -- via IBN – Annovis Bio Inc. (NYSE: ANVS) (\"Annovis\" or the \"Company\"), a late-stage clinical drug platform company pioneering transformative therapies ","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/05/3021101/0/en/Annovis-Announces-First-Patients-Entered-into-Pivotal-Phase-3-Study-of-Buntanetap-for-Early-Alzheimer-s-Disease.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1169590202.USD","LU0251143458.SGD","BK4523","LU0828237940.HKD","LU1868837565.USD","LU0261950470.USD","IE00BYTNYM70.SGD","LU1868838027.USD","IBN","PD","LU0264410563.USD","LU0164881194.USD","LU0143863198.USD","LU1169589451.USD","LU0143863784.USD","BK4585","BK4023","SG9999004220.SGD","BK4535","LU1868837722.USD","LU1102505929.USD","LU0181495838.USD","LU0823039010.USD","LU0823038988.USD","LU0531971678.HKD","LU1102505762.USD","BK4139","LU0048575426.USD","ANVS","BK4548","LU0066902890.USD","LU1481012133.USD","BK4588","IE00B7N09G41.SGD","IE00B0JY6M65.USD","BK4207"],"gpt_icon":0},{"id":"2509413664","title":"BRIEF-Annovis Bio Announces Closing Of $21 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2509413664","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509413664?lang=en_us&edition=fundamental","pubTime":"2025-02-05 06:49","pubTimestamp":1738709348,"startTime":"0","endTime":"0","summary":"BRIEF-Annovis Bio Announces Closing Of $21 Million Public OfferingFeb 4 (Reuters) - Annovis Bio Inc ANVS.N:ANNOVIS BIO, INC. ANNOUNCES CLOSING OF $21 MILLION PUBLIC OFFERINGANNOVIS BIO INC - PROCEEDS ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250204:nTUAB0JJPG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANVS","BK4139"],"gpt_icon":0},{"id":"2509492654","title":"Annovis Bio, Inc. Announces Closing of $21 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2509492654","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509492654?lang=en_us&edition=fundamental","pubTime":"2025-02-05 05:31","pubTimestamp":1738704660,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250204:nTUAB0JJPG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ANVS"],"gpt_icon":0},{"id":"2509492617","title":"Annovis Bio Inc - Proceeds to Fund Phase 3 Study of Buntanetap for Alzheimer's","url":"https://stock-news.laohu8.com/highlight/detail?id=2509492617","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2509492617?lang=en_us&edition=fundamental","pubTime":"2025-02-05 05:31","pubTimestamp":1738704660,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250204:nTUAB0JJPG:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ANVS"],"gpt_icon":0},{"id":"2508124561","title":"Sector Update: Health Care Stocks Higher Monday Afternoon","url":"https://stock-news.laohu8.com/highlight/detail?id=2508124561","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508124561?lang=en_us&edition=fundamental","pubTime":"2025-02-04 03:03","pubTimestamp":1738609380,"startTime":"0","endTime":"0","summary":"Health care stocks were higher Monday afternoon, with the NYSE Health Care Index up 0.2% and the Health Care Select Sector SPDR Fund  adding 0.6%.The iShares Biotechnology ETF  shed 0.3%.In corporate news, IDEXX Laboratories  shares jumped 12% after the company reported quarterly earnings that beat estimates.Becton Dickinson  is considering a potential separation of its life science division, according to media reports. Becton Dickinson shares were up 0.6%.Annovis Bio  shares fell nearly 30%. The company said it priced an underwritten public offering of 5.25 million shares and warrants to buy 5.25 million shares at a combined price of $4 per share.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0266013472.USD","BK4082","LU0690374615.EUR","LU1989771016.USD","BK4585","LU1571399168.USD","BK7067","LU0289739343.SGD","LU0511384066.AUD","LU1941712264.USD","BK4139","BDX","GB00B4QBRK32.GBP","BDX.AU","ANVS","GB00B4LPDJ14.GBP","IBB","LU1854103824.USD","LU2404859741.USD","IE00BFXG1179.USD","LU1059921491.USD","BK4567","LU1941712348.USD","IDXX","LU0170899867.USD","LU1894683264.USD","BK4504","LU0289961442.SGD","LU2404859667.USD","LU1894683348.USD","BK4581","BK4588","LU1854104046.USD","LU1291159041.SGD","XLV","LU0690374961.EUR"],"gpt_icon":0},{"id":"2508236421","title":"Annovis Bio Prices $21 Million Public Offering; Shares Fall Sharply","url":"https://stock-news.laohu8.com/highlight/detail?id=2508236421","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508236421?lang=en_us&edition=fundamental","pubTime":"2025-02-04 00:55","pubTimestamp":1738601729,"startTime":"0","endTime":"0","summary":"Annovis Bio  said Monday it priced an underwritten public offering of about 5.3 million common shares and warrants to buy 5.3 million common shares at a combined price of $4 per share.The company said the warrants will have an exercise price of $5 per share.Total gross proceeds from the offering, which is expected to close on Tuesday, are expected to be $21 million, the company said.Annovis Bio said it plans to use the net proceeds mainly for working capital and general corporate purposes, including the continued clinical development of its lead compound, Buntanetap.The company's shares slipped past 30% in recent trading.Price: 3.40, Change: -1.48, Percent Change: -30.29","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","ANVS"],"gpt_icon":0},{"id":"2508144622","title":"Annovis Bio falls -25.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2508144622","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508144622?lang=en_us&edition=fundamental","pubTime":"2025-02-03 23:00","pubTimestamp":1738594855,"startTime":"0","endTime":"0","summary":"Annovis Bio (ANVS) is down -25.6%, or -$1.25 to $3.62. Published first on TheFly – the ultimate source for real-time, market-moving breaking financ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/annovis-bio-falls-25-6?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/annovis-bio-falls-25-6?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ANVS"],"gpt_icon":0},{"id":"2508108021","title":"Top Premarket Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2508108021","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508108021?lang=en_us&edition=fundamental","pubTime":"2025-02-03 20:49","pubTimestamp":1738586997,"startTime":"0","endTime":"0","summary":"Focus Universal  shares retreated 22% pre-bell Monday, paring Friday's rally.SR Bancorp  shares fell 20% after the company reported late Friday lower Q4 earnings and revenue.Annovis Bio  shares dropped 18% following a muted session.Unisys Corporation  shares were down 3% after a 1.5% decline in the previous session.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SRBK","BK4211","BK4139","UIS","ANVS","BK4157","BK4134","FCUV"],"gpt_icon":0},{"id":"2508112368","title":"BUZZ-U.S. STOCKS ON THE MOVE-General Motors, Alibaba.com, Annovis Bio","url":"https://stock-news.laohu8.com/highlight/detail?id=2508112368","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508112368?lang=en_us&edition=fundamental","pubTime":"2025-02-03 20:06","pubTimestamp":1738584382,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-General Motors, Alibaba.com, Annovis Bio Eikon search string for individual stock moves: STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call news","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"4298a089b260d9091925a4c194be9e97","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250203:nL4N3OU0W4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MACW.SI","BSX","F","BABA","NVDS.UK","UEC","TAP","NVDU","NVD3.UK","STZ","BAC","TSLA","ANVS","GL","CCJ","2NVD.UK","09618","09988","NVDA","ISRG","GM","NVIW.SI","SNVD.UK","NVDD","89618","TSYW.SI","NVD2.UK","NVDS","USAW.SI","09626","MSFT","PGR","ALL","3NVD.UK"],"gpt_icon":1},{"id":"2508149721","title":"BUZZ-Annovis Bio slides after $21 mln stock offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2508149721","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508149721?lang=en_us&edition=fundamental","pubTime":"2025-02-03 19:52","pubTimestamp":1738583532,"startTime":"0","endTime":"0","summary":"BUZZ-Annovis Bio slides after $21 mln stock offering** Shares of drug developer Annovis Bio ANVS.N drop 17.7% to $4.01 premarket** ANVS announces pricing of public offering of 5.25 mln shares of common stock and warrants at $4/shr for gross proceeds of $21 mln** Stock offering priced at a 17.9% discount to stock's last close     ** ThinkEquity was the sole book-running manager for the offering** ANVS plans to use the proceeds for working capital and general purposes, including the development of its lead experimental drug, Buntanetap** Prior to offering, ANVS had ~14.3 mln outstanding shares, per SEC filing, giving it a market cap of $69.3 mln as of last close  ** ANVS stock slumped 73.1% in 2024  ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250203:nL4N3NA1KP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ANVS","BK4139"],"gpt_icon":0},{"id":"2508911134","title":"Annovis Bio Inc - Prices Public Offering of 5.25 Mln Shares at $4.00 Each","url":"https://stock-news.laohu8.com/highlight/detail?id=2508911134","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508911134?lang=en_us&edition=fundamental","pubTime":"2025-02-03 19:22","pubTimestamp":1738581766,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250203:nTUA3YWYRT:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ANVS","BK4139"],"gpt_icon":0},{"id":"2508311157","title":"Annovis Bio, Inc. Announces Pricing of $21 Million Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2508311157","media":"GlobeNewswire","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508311157?lang=en_us&edition=fundamental","pubTime":"2025-02-03 19:22","pubTimestamp":1738581720,"startTime":"0","endTime":"0","summary":"MALVERN, Pa., Feb.  03, 2025  (GLOBE NEWSWIRE) -- via IBN – Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/03/3019319/0/en/Annovis-Bio-Inc-Announces-Pricing-of-21-Million-Public-Offering.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0251143458.SGD","LU0264410563.USD","LU1169589451.USD","LU1102505929.USD","PD","BK4535","SG9999004220.SGD","IE00BYTNYM70.SGD","LU1868837722.USD","LU0823038988.USD","BK4523","LU0261950470.USD","LU1868837565.USD","BK4139","LU0164881194.USD","BK4023","LU1481012133.USD","LU1169590202.USD","ANVS","BK4588","LU0181495838.USD","IBN","LU1102505762.USD","BK4585","IE00B7N09G41.SGD","LU0531971678.HKD","LU1868838027.USD","BK4207","LU0143863198.USD","BK4548","LU0828237940.HKD","LU0823039010.USD","LU0066902890.USD","IE00B0JY6M65.USD","LU0048575426.USD","LU0143863784.USD"],"gpt_icon":0},{"id":"2508914992","title":"Annovis Bio, Inc. Announces Proposed Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2508914992","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508914992?lang=en_us&edition=fundamental","pubTime":"2025-02-01 09:14","pubTimestamp":1738372442,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250201:nTUA6ZBFCV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","ANVS"],"gpt_icon":0},{"id":"2508391426","title":"Annovis Bio, Inc. Announces Proposed Public Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2508391426","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508391426?lang=en_us&edition=fundamental","pubTime":"2025-02-01 09:14","pubTimestamp":1738372440,"startTime":"0","endTime":"0","summary":"MALVERN, Pa., Jan.  31, 2025  (GLOBE NEWSWIRE) -- via IBN – Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/01/3019065/0/en/Annovis-Bio-Inc-Announces-Proposed-Public-Offering.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1868837722.USD","LU0143863198.USD","ANVS","LU0143863784.USD","IE00B0JY6M65.USD","BK4585","LU1102505762.USD","LU1169589451.USD","LU1169590202.USD","LU1868838027.USD","PD","BK4535","LU1102505929.USD","LU0828237940.HKD","IBN","BK4523","LU1868837565.USD","LU0251143458.SGD","BK4023","LU0048575426.USD","LU0823038988.USD","BK4548","LU0261950470.USD","LU0164881194.USD","BK4588","LU0066902890.USD","LU1481012133.USD","LU0264410563.USD","LU0181495838.USD","LU0823039010.USD","IE00B7N09G41.SGD","SG9999004220.SGD","BK4207","BK4139","LU0531971678.HKD","IE00BYTNYM70.SGD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.annovisbio.com","stockEarnings":[{"period":"1week","weight":-0.0714},{"period":"1month","weight":-0.4336},{"period":"3month","weight":-0.6009},{"period":"6month","weight":-0.68},{"period":"1year","weight":-0.758},{"period":"ytd","weight":-0.4573}],"compareEarnings":[{"period":"1week","weight":0.0149},{"period":"1month","weight":0.0285},{"period":"3month","weight":0.0409},{"period":"6month","weight":0.0999},{"period":"1year","weight":0.2145},{"period":"ytd","weight":0.0403}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which is in Phase 3 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405 for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.","yearOnYearQuotes":[{"month":1,"riseRate":0.4,"avgChangeRate":-0.00486},{"month":2,"riseRate":0.333333,"avgChangeRate":0.100809},{"month":3,"riseRate":0.4,"avgChangeRate":-0.008916},{"month":4,"riseRate":0.2,"avgChangeRate":-0.160489},{"month":5,"riseRate":0.6,"avgChangeRate":0.247553},{"month":6,"riseRate":0.6,"avgChangeRate":0.216567},{"month":7,"riseRate":0.6,"avgChangeRate":0.066217},{"month":8,"riseRate":0.4,"avgChangeRate":-0.05366},{"month":9,"riseRate":0.4,"avgChangeRate":-0.049402},{"month":10,"riseRate":0.2,"avgChangeRate":-0.090551},{"month":11,"riseRate":0.6,"avgChangeRate":0.036162},{"month":12,"riseRate":0.4,"avgChangeRate":0.213127}],"exchange":"NYSE","name":"Annovis Bio, Inc.","nameEN":"Annovis Bio, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.2","shortVersion":"4.30.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Annovis Bio, Inc.(ANVS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Annovis Bio, Inc.(ANVS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Annovis Bio, Inc.,ANVS,Annovis Bio, Inc.股票,Annovis Bio, Inc.股票老虎,Annovis Bio, Inc.股票老虎国际,Annovis Bio, Inc.行情,Annovis Bio, Inc.股票行情,Annovis Bio, Inc.股价,Annovis Bio, Inc.股市,Annovis Bio, Inc.股票价格,Annovis Bio, Inc.股票交易,Annovis Bio, Inc.股票购买,Annovis Bio, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Annovis Bio, Inc.(ANVS),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Annovis Bio, Inc.(ANVS) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}